Real-World Treatment Patterns Among Patients With Scalp Psoriasis in Canada
Author(s)
Ron Vender, MD, FRCPC1, Steven Aviv, BSc2, Jessica Weiss, MSc2, Michelle Nguyen, MSc2, Clarabella Yim, MSc3, Brett Stephenson, PharmD3;
1McMaster University, Division of Dermatology, Hamilton, ON, Canada, 2Pentavere Research Group, Toronto, ON, Canada, 3Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA
1McMaster University, Division of Dermatology, Hamilton, ON, Canada, 2Pentavere Research Group, Toronto, ON, Canada, 3Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA
Presentation Documents
OBJECTIVES: To determine the prevalence and the use of advanced systemic therapies in patients with scalp psoriasis in Canada.
METHODS: This retrospective chart review of patients diagnosed with plaque psoriasis from 30-June-2019 to 30-September-2024 was conducted using the nationally representative DERMAID database. Data were extracted using DARWENTM, a validated artificial intelligence platform that extracts written clinical data from patients’ electronic medical records into DERMAID. Data extracted included the diagnosis of plaque psoriasis, the presence of scalp involvement, and the use of advanced systemic treatments specific to plaque psoriasis (oral phosphodiesterase 4 inhibitors, oral Janus kinase inhibitors, or a biologic therapy). Body surface area (BSA) was also extracted, to understand its effect on treatment patterns.
RESULTS: Overall, 34% of patients with plaque psoriasis in the DERMAID database had disease present in their scalp. More than half of the patients with scalp psoriasis were treated with an advanced systemic therapy; the three most common were risankizumab (26%), guselkumab (18%), and apremilast (10%). Of patients with scalp psoriasis, 64% had BSA <10% at diagnosis and 20% of these patients were treated with an advanced systemic therapy. The three most common advanced systemic therapies used were risankizumab (30%), guselkumab (16%), and apremilast (12%).
CONCLUSIONS: Scalp psoriasis was present in a substantial proportion of patients with plaque psoriasis in Canada, identified in more than one-third of patients in the DERMAID database. Patients with scalp psoriasis are likely to receive advanced systemic therapy, with more than half of the patients having received this treatment. Even when BSA <10% is present, indicative of mild-to-moderate psoriasis that can be managed topically, a sizable proportion of patients (20%) received advanced therapy. Currently, there is a large unmet need for innovative topical treatments for scalp psoriasis, which can be used prior to advanced systemic therapy.
METHODS: This retrospective chart review of patients diagnosed with plaque psoriasis from 30-June-2019 to 30-September-2024 was conducted using the nationally representative DERMAID database. Data were extracted using DARWENTM, a validated artificial intelligence platform that extracts written clinical data from patients’ electronic medical records into DERMAID. Data extracted included the diagnosis of plaque psoriasis, the presence of scalp involvement, and the use of advanced systemic treatments specific to plaque psoriasis (oral phosphodiesterase 4 inhibitors, oral Janus kinase inhibitors, or a biologic therapy). Body surface area (BSA) was also extracted, to understand its effect on treatment patterns.
RESULTS: Overall, 34% of patients with plaque psoriasis in the DERMAID database had disease present in their scalp. More than half of the patients with scalp psoriasis were treated with an advanced systemic therapy; the three most common were risankizumab (26%), guselkumab (18%), and apremilast (10%). Of patients with scalp psoriasis, 64% had BSA <10% at diagnosis and 20% of these patients were treated with an advanced systemic therapy. The three most common advanced systemic therapies used were risankizumab (30%), guselkumab (16%), and apremilast (12%).
CONCLUSIONS: Scalp psoriasis was present in a substantial proportion of patients with plaque psoriasis in Canada, identified in more than one-third of patients in the DERMAID database. Patients with scalp psoriasis are likely to receive advanced systemic therapy, with more than half of the patients having received this treatment. Even when BSA <10% is present, indicative of mild-to-moderate psoriasis that can be managed topically, a sizable proportion of patients (20%) received advanced therapy. Currently, there is a large unmet need for innovative topical treatments for scalp psoriasis, which can be used prior to advanced systemic therapy.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD76
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)